A Phase 3 interventional study of Riboflavin and VEGA UV-A Illumination System in Keratoconus and Ectasia, sponsored by Topcon Medical Systems, Inc.. Terminated at 13 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-06-29.
Sponsored by Topcon Medical Systems, Inc. (part of Topcon Corporation) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing riboflavin in Keratoconus — 5 open to participants now, 8 under way, 7 of them phase 3. Riboflavin · Keratoconus.
Among the 23 studies testing riboflavin in Keratoconus, this one is the 5th largest by enrollment, is one of 6 that started in 2010, is one of 12 in phase 3, and was the 8th registered.
313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.
Browse Keratoconus studies →5 of the 23 studies testing riboflavin in Keratoconus are open now, in 1 country. Recruiting first, the newest first:
Price Vision Group · Sites in United States
Ages 10–90
Cornea and Laser Eye Institute · Sites in United States
Ages 18+ · Healthy volunteers
Cornea and Laser Eye Institute · Sites in United States
Ages 12+ · Healthy volunteers
Cornea and Laser Eye Institute · Sites in United States
Ages 12+ · Healthy volunteers
Kent Wellish MD
Ages 12+
By country, each count listing its studies:
Riboflavin: first FDA approval 1953 (M.V.I.-12 ADULT). What it is approved for, and how studies give it, is on its page →
Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 16 · Phase 4 1
First in 2008; this study’s year is marked. 6 started in 2010.
This study's enrollment of 500 is above the median of 40 across 205 interventional studies indexed under Keratoconus.
Median enrollment 170 across the 23 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Topcon Medical Systems, Inc., one of the names counted as Topcon Corporation. Under that name alone:
Topcon Medical Systems, Inc. is the lead sponsor of 26 studies on the registry; none are open to participants now.
Topcon Corporation has 2 studies filed under Keratoconus — fewer than ten, so there is no comparison to draw.
1 of the studies testing riboflavin in Keratoconus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04731727Kent Wellish MDTreating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing riboflavin in Keratoconus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to evaluate the long tern safety and effectiveness of cross-linking in eyes with keratoconus and ectasia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All eyes to be treated with riboflavin and UV light
Drug: Riboflavin · Device: VEGA UV-A Illumination System
Riboflavin is a solution that will be delivered to the treatment area
This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
Changes in Corneal Curvature
Time frame: 24 MO
The recruitment period started December 2010 and ended June 2012 at medical clinics throughout the country.
| Milestone | CXL Treatment |
|---|---|
| Started | 372 |
| Completed | 0 |
| Not completed | 372 |
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CXL Treatment | — | 0/372 (0%) | 0/372 (0%) |
| Age, Categorical(Participants) | CXL Treatment |
|---|---|
| <=18 years | NA |
| Between 18 and 65 years | NA |
| >=65 years | NA |
| Age, Continuous(years) | CXL Treatment |
|---|---|
| Mean | NA ± NA |
| Sex: Female, Male(Participants) | CXL Treatment |
|---|---|
| Female | NA |
| Male | NA |
| Region of Enrollment(participants) | CXL Treatment |
|---|---|
| United States | 372 |
The record gives a start of Dec 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riboflavin
Topcon Medical Systems, Inc. →